Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of F-FLT PET.

An emerging noninvasive approach to assess tissue proliferation uses the PET tracer 3'-deoxy-3'-F-fluorothymidine (F-FLT). To evaluate the diagnostic value of this technique in myelofibrosis, F-FLT PET imaging results were compared with bone marrow histology and bone marrow scintigraphy (BMS), the gold standard techniques in this clinical situation. Fifteen patients with histology-proven myelofibrosis were included consecutively in the study.

An optimised radiolabel procedure to prepare (99m)Tc-colloidal rhenium sulphide to improve radiochemical purity.

Background: More than 25% of 99mTc colloidal rhenium sulphide preparations have been reported to have a radiochemical purity of <95% in 11 radiopharmacies.

Objectives: To identify the key parameters involved in radiochemical purity, different preparation procedures were analysed to develop an optimised preparation method.

Methods: In the first part of this study, various data such as the Nanocis kit batch number, the eluate volume, the time between the two final elutions, the temperature and duration of heating were collected and analysed to determine the critical parameters that significantly decrease radiochemical purity.

[Basics of PET and PET/CT imaging: instrumentation and radiopharmaceuticals for clinical diagnosis].

Positron emission tomography (PET), like scintigraphy, is a type of functional and molecular imaging. Image resolution is better than with scintigraphy, and tomographic slices are obtained, as with CT and MRI. Modern PET machines are coupled with CT (PET/CT) and yield fused images that combine metabolic and anatomic approaches.

Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

Unlabelled: The aim of this study was to evaluate whether (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET is accurate for the diagnosis and follow-up of any type of well-differentiated digestive endocrine tumor and to assess its performance compared with standard somatostatin receptor scintigraphy (SRS) using (111)In-pentetreotide.

Methods: We reviewed the results of 33 evaluable (18)F-FDOPA PET and (111)In-pentetreotide SRS examinations performed between March 2002 and September 2005 in 30 patients referred for documented well-differentiated digestive endocrine tumor.

Results: The sensitivity and accuracy of (18)F-FDOPA PET were significantly better for carcinoid tumors (defined according to the World Health Organization 2000 classification) (n = 19) than for noncarcinoid tumors (n = 14)-that is, 93% versus 25% for sensitivity (P < 0.

Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET.

Objectives: To assess the clinical performance of fluorodeoxyglucose positron emission tomography (FDG PET) using either a coincidence (CDET) gamma camera or PET equipment with Nal crystals for the detection of recurrences of colorectal cancer.

Methods: From July 1997 to December 1999, 290 examinations were performed in 244 patients using a CDET gamma camera (2-dimensional system with 19 mm thick crystals). Additionally, from January 2000 to July 2002, 354 examinations were performed in 303 patients using PET (3-dimensional system with Nal crystals).

Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Small cell lung carcinomas (SCLC) express neuroendocrine markers, and dihydroxyphenylalanine (DOPA) is known to accumulate in neuroendocrine tumours. This study was performed with the aim of evaluating the uptake of 3,4-dihydroxy-6-(18)F-fluoro-phenylalanine ([(18)F]FDOPA) by SCLC, based on comparison with the results of fluorine-18 fluorodeoxyglucose ([(18)F]FDG) positron emission tomography (PET) and standard imaging procedures. [(18)F]FDG PET and [(18)F]FDOPA PET were performed on four patients with newly diagnosed SCLC.